Researchmoz added Most up-to-date research on "Global Post Menopausal Vaginal Atrophy Drugs Market 2016-2020" to its huge collection of research reports.
Vaginal atrophy also known as atrophic vaginitis is defined as a decrease in the production of estrogen after menopause, leading to thinning, drying, and reduced elasticity of the vaginal tissues. Up to 40% of post-menopausal women have symptoms of atrophic vaginitis. It typically affects women in the age group of 45-55 years. PVA result in symptoms such as itching, burning, dryness, and dyspareunia. Topical preparations such as hormone replacement therapy (HRT) and estrogen creams are used to treat PVA.
Technavios analysts forecast the global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global PVA drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of drugs (creams, tablets, patches, and rings) used to treat PVA.
The market is divided into the following segments based on geography:
Americas
EMEA
APAC
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=711490
Technavio's report, Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Pfizer Inc.
Allergan Inc.
Shionogi & Co. Ltd.
Novo Nordisk A/S
Teva Pharmaceutical Industries Ltd.
Other prominent vendors
Bayer
Bionovo
EndoCeutics
Foamix Pharmaceuticals
Ligand Pharmaceuticals
Pantarhei Bioscience
Pep-Tonic Medical
TherapeuticsMD
Upsher-Smith Laboratories
Market driver
Favorable healthcare reforms in the US
For a full, detailed list, view our report
Market challenge
Patent expiry of branded products
For a full, detailed list, view our report
Market trend
Paradigm shift to non-estrogenic therapies
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=711490
Vaginal atrophy also known as atrophic vaginitis is defined as a decrease in the production of estrogen after menopause, leading to thinning, drying, and reduced elasticity of the vaginal tissues. Up to 40% of post-menopausal women have symptoms of atrophic vaginitis. It typically affects women in the age group of 45-55 years. PVA result in symptoms such as itching, burning, dryness, and dyspareunia. Topical preparations such as hormone replacement therapy (HRT) and estrogen creams are used to treat PVA.
Technavios analysts forecast the global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global PVA drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of drugs (creams, tablets, patches, and rings) used to treat PVA.
The market is divided into the following segments based on geography:
Americas
EMEA
APAC
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=711490
Technavio's report, Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Pfizer Inc.
Allergan Inc.
Shionogi & Co. Ltd.
Novo Nordisk A/S
Teva Pharmaceutical Industries Ltd.
Other prominent vendors
Bayer
Bionovo
EndoCeutics
Foamix Pharmaceuticals
Ligand Pharmaceuticals
Pantarhei Bioscience
Pep-Tonic Medical
TherapeuticsMD
Upsher-Smith Laboratories
Market driver
Favorable healthcare reforms in the US
For a full, detailed list, view our report
Market challenge
Patent expiry of branded products
For a full, detailed list, view our report
Market trend
Paradigm shift to non-estrogenic therapies
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=711490
No comments:
Post a Comment